MAP3K9
| Official symbol: | MAP3K9 |
| Full name: | mitogen-activated protein kinase kinase kinase 9 |
| Location: | 14q24.2 |
| Also known as: | MLK1, PRKE1, MEKK9 |
| Entrez ID: | 4293 |
| Ensembl ID: | ENSG00000006432 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.47 |
|
|
|
| Recurrently deleted in 3 cancer type(s) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | NA |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
RNAi: STRONGLY SELECTIVE
|
|
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 24.70 (Percentile rank: 50.94%) |
| PubTator score: | 11.13 (Percentile rank: 41.90%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
| Tractability (antibody): | |
